Thierry Cournez

DINAMIQS, a Siegfried company, today inaugurated its state-of-the-art cGMP manufacturing facility for viral vectors — the first of its kind in Switzerland. The new facility enables end-to-end manufacturing of viral vector gene therapies, from molecule design to aseptic drug product filling. Read the media release: https://lnkd.in/eRgqbgpj

208

2 commentaires

🔬 Advancing the Future of Biologics Manufacturing We’re excited to announce our strategic collaboration with Gearbox Biosciences to co-develop cutting-edge technologies for plasmid DNA (pDNA) manufacturing — a key component in mRNA therapies, gene therapies, and vaccines. We previously developed an antibiotic-free system for recombinant pharmaceutical protein, leveraging our ESETEC® platform. This partnership combines WACKER’s expertise in GMP biologics production with Gearbox Biosciences’ innovative Pop-Out-Plasmid® technology, enabling antibiotic-free, scalable, and cost-effective pDNA workflows. 💡 Together, we aim to: 🔹Revolutionize manufacturing of pDNA 🔹Improve sustainability and regulatory compliance 🔹Accelerate timelines from lab to clinic The collaboration is already underway at our newly opened WACKER Biotechnology Center in Munich, with promising milestones ahead. Read more in the press release about this exciting partnership 👉 http://wch.ag/12P550WAuEO #pDNA #Biotech #CDMO #LifeSciences #GeneTherapy

197

3 commentaires

[NEWS] Biocytogen Announces ADC Innovator Tubulis GmbH Has Signed Global Exclusive License Agreement for Single Antibody Biocytogen, a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that ADC therapeutics developer, Tubulis has exercised an exclusive license for the global development and commercialization of a fully human antibody developed by Biocytogen. The antibody will be applied in a novel ADC candidate proprietary to Tubulis. It is part of a previously signed research collaboration and option agreement to discover and advance antibody components for the development and commercialization of ADC products based on Biocytogen’s antibody discovery engine. The antibody was generated using Biocytogen’s proprietary RenMice® platform and features high affinity, low immunogenicity, and favorable developability. Tubulis will apply its proprietary linker and payload technologies to develop innovative ADC therapies based on this antibody, aiming to address areas of high unmet clinical need in cancer treatment. Dr. Yuelei Shen, President and CEO of Biocytogen, said, “We are very pleased that Tubulis has exercised its option, which reflects the international competitiveness and translational potential of our fully human antibody discovery platform. We look forward to seeing this antibody advance through Tubulis’ powerful ADC development engine and into clinical development to benefit patients around the world.” Jonas Helma-Smets, PhD, CSO and co-founder of Tubulis, stated: “Our goal is to drive innovation in ADC development and deliver uniquely positioned ADC therapeutics that can improve treatment outcomes to patients with solid tumors. The R&D collaboration with Biocytogen has yielded an antibody candidate that we believe fits well with our ADC technology platforms and that may support us in the development of a novel therapeutic candidate.” Under the terms of the agreement, Biocytogen will receive an upfront payment and is eligible for certain development, regulatory, and commercial milestone payments, and single-digit royalties on net sales. #Biocytogen #Tubulis #AntibodyDiscovery #RenMicePlatform #ADCTherapeutics #CancerTherapeutics #OncologyInnovation #DrugDevelopment #BiotechCollaboration #NovelTherapeutics #BiopharmaPartnerships

105

2 commentaires

Visualizing small proteins – a crucial part of understanding disease drivers – has long been one of the toughest challenges in cryo-electron microscopy. Our scientists have overcome this obstacle by developing “Rigid Fabs,” a groundbreaking innovation which can transform antibody fragments into rigid scaffolds, making it possible to capture high-resolution images of small proteins. The video shows we are able to resolve small proteins to high resolution by cryoEM using our newly developed technology. Read more about this advancement in Nature Communications to learn how this technology is paving the way for accelerated drug discovery. http://spr.ly/6040A9no6

231

5 commentaires

In today’s pharma and biotech landscape, innovators are doubling down on discovery — and increasingly looking to trusted partners to bring those breakthroughs to life. We’ve chosen to embrace the industry shift, moving beyond the role of a traditional CDMO to become a true extension of our partners’ operations — building global capacity, integrating cutting-edge technology, and investing strategically to meet the demands of the most complex therapies. We invite you to read about how we have established a network of sites, including our landmark facility in Holly Springs, NC to deliver speed, scale, and adaptability. The future of biopharmaceutical manufacturing demands agility, precision, and partnership at a global scale. You can find the full article here: https://lnkd.in/dbEwVRRZ #Biopharma #CDMO #Innovation #DrugDevelopment

152

6 commentaires

July 1st, 2025 – Enzo Biochem, a leader in labeling and detection technologies, is pleased to announce a successful collaboration with Roche Diagnostics France to validate its AMPIVIEW® probes for use with the Ventana DISCOVERY ULTRA Platform, an advanced and customizable automated tissue staining system. AMPIVIEW® probes are powered by Enzo’s proprietary LoopRNA™ ISH technology, consisting of RNA probes complementary to DNA or RNA target sequences, interspersed with loops of a chosen hapten. This patented technology combined with a multiple hybridization regions and single probe design allows a highly specific and sensitive visualization of nucleic acids at the single cell level. As a result of this new collaboration, users of the Roche DISCOVERY ULTRA Platform can now benefit from multiple advantages: * Access to New Biomarkers * Streamlined Workflow: Automated protocols minimize variability and hands-on time. * Reliable, Reproducible Data: Trusted Enzo probe performance paired with Roche’s robust platform automation and optimized protocols. * Scalable for High-Throughput: Ideal for labs processing large tissue sample volumes. * Flexible Assay Design: Supports both Singleplex and complex Multiplex ISH experiments with both chromogenic and fluorescent detection formats. For more information about ENZO’s validated ISH probes on the Roche DISCOVERY ULTRA Platform, please visit: https://lnkd.in/gz2yGSUQ *RUO – Research Use Only For Research Use Only – Not for use in diagnostic procedures

60

7 commentaires